Last reviewed · How we verify
TP-1454 monotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TP-1454 monotherapy (TP-1454 monotherapy) — Sumitomo Pharma America, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TP-1454 monotherapy TARGET | TP-1454 monotherapy | Sumitomo Pharma America, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TP-1454 monotherapy CI watch — RSS
- TP-1454 monotherapy CI watch — Atom
- TP-1454 monotherapy CI watch — JSON
- TP-1454 monotherapy alone — RSS
Cite this brief
Drug Landscape (2026). TP-1454 monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/tp-1454-monotherapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing